These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28865938)

  • 1. [A "fast track" to improve management of neovascular age related macular degeneration].
    Krivosic V; Philippakis E; Couturier A; Dupas B; Erginay A; Desmettre T; Streho M; Bonnin S; Mane V; Jouvaud S; Gualino V; Durand D; Tadayoni R
    J Fr Ophtalmol; 2017 Oct; 40(8):642-647. PubMed ID: 28865938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Interest of optical coherence tomography performed immediately before intravitreal injection of anti-VEGF in exudative AMD].
    Moyal L; Cohen SY; Pedinielli A; Semoun O; Lalloum F; Jung C; Souied E
    J Fr Ophtalmol; 2015 Sep; 38(7):573-9. PubMed ID: 25997681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Real life visual and anatomic outcomes of aflibercept treatment for treatment-naive patients with exudative age-related macular degeneration].
    Duval MV; Rougier MB; Delyfer MN; Combillet F; Korobelnik JF
    J Fr Ophtalmol; 2017 Apr; 40(4):270-278. PubMed ID: 28341388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept.
    Kaya F
    J Fr Ophtalmol; 2017 Dec; 40(10):832-838. PubMed ID: 29113742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies.
    Lanzetta P; Cruess AF; Cohen SY; Slakter JS; Katz T; Sowade O; Zeitz O; Ahlers C; Mitchell P
    Acta Ophthalmol; 2018 Dec; 96(8):e911-e918. PubMed ID: 29659183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WRINKLED VASCULARIZED RETINAL PIGMENT EPITHELIUM DETACHMENT PROGNOSIS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Lam D; Semoun O; Blanco-Garavito R; Jung C; Nguyen DT; Souied EH; Mimoun G
    Retina; 2018 Jun; 38(6):1100-1109. PubMed ID: 28520639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
    Kvannli L; Krohn J
    Acta Ophthalmol; 2017 Nov; 95(7):678-682. PubMed ID: 28139082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the efficacy of aflibercept's in the treatment of neovascular age-related macular degeneration in treatment-naive and switched patients. Report of 86 cases].
    Maringe E; Letesson E; Duncombe A; Muraine M; Genevois O
    J Fr Ophtalmol; 2016 Mar; 39(3):255-60. PubMed ID: 26995074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal ranibizumab for neovascular age-related macular degeneration patients with good baseline visual acuity and the predictive factors for visual outcomes.
    Ozkaya A; Alkin Z; Osmanbasoglu OA; Ozkaya HM; Demirok A
    J Fr Ophtalmol; 2014 Apr; 37(4):280-7. PubMed ID: 24657215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Clinical Outcome and Prognostic Indicators.
    Vogel RN; Davis DB; Kimura BH; Rathinavelu S; Graves GS; Szabo A; Han DP
    Retina; 2017 Feb; 37(2):257-264. PubMed ID: 27429385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of age-related macular degeneration: Expert opinion and therapeutic algorithm].
    Kodjikian L; Fourmaux E; Coscas F; Dumas S; Français C; Morel C; Oubraham H; Razavi S
    J Fr Ophtalmol; 2015 Sep; 38(7):639-45. PubMed ID: 26314897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranibizumab for exudative age-related macular degeneration: A five year study of adherence to follow-up in a real-life setting.
    Boulanger-Scemama E; Querques G; About F; Puche N; Srour M; Mane V; Massamba N; Canoui-Poitrine F; Souied EH
    J Fr Ophtalmol; 2015 Sep; 38(7):620-7. PubMed ID: 25913443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
    Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
    Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inner retinal layer change in glaucoma patients receiving anti-VEGF for neovascular age related macular degeneration.
    Saleh R; Karpe A; Zinkernagel MS; Munk MR
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):817-824. PubMed ID: 28127658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two year outcome in treatment-naive patients with neovascular age-related macular degeneration (nAMD) using an individualized regimen of Aflibercept.
    Barakat A; Rufin V; Tran THC
    J Fr Ophtalmol; 2018 Sep; 41(7):603-610. PubMed ID: 30166233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept.
    Tyagi P; Juma Z; Hor YK; Scott NW; Ionean A; Santiago C
    BMC Ophthalmol; 2018 Jun; 18(1):148. PubMed ID: 29929478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
    Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
    Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization.
    Van Lancker L; Petrarca R; Moutsouris K; Masaoutis P; Kampougeris G
    Eur J Ophthalmol; 2017 May; 27(3):342-345. PubMed ID: 27739561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.